Cambridge cancer drug startup eyes $40M IPO eight months after launch

Less than a year after emerging from stealth mode, Cambridge cancer drug startup Cue Biopharma has disclosed plans to raise up to $40 million in an initial public offering. The 26-employee company said in a federal filing on Thursday that it had applied to list its stock under the ticker “CUE” on the Nasdaq Capital Market, which focuses on smaller, early-stage companies. Cue was founded in 2015 with $10 million in seed funding, and scored another $16 million when it came out of stealth mode…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news